Recently, BG Medicine (BGMD) entered in a research collaboration agreement with leading medical devices player, Boston Scientific Corporation (NYSE:BSX). The two companies will study the role of galectin-3 to help screening of patients who would derive the maximum benefit from the cardiac-resynchronization therapy (CRT) and would use patient data from the MADIT-CRT trial. CRT is [...]